ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ruzasvir

Also written as “Ruzasvir”, “Bemnifosbuvir/Ruzasvir (BEM/RZR)” and “Ruzasvir 60 mg”.

Its studies are mostly in Hepatitis C, Chronic · Hepatitis C, led by 2 companies.

Drug pageRuzasvir: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jan 6, 20157 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck50 open or runningphase 2since Jan 6, 2015Feb 27, 2014none ahead
Atea Pharmaceuticalsits history only20 open or runningphase 2since Jun 6, 2023Jun 6, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 27, 2014First study: phase 1 study in Hepatitis CFirst studyNCT02076100 · 22 enrolled
  2. Jan 6, 2015Phase 2 study in Hepatitis CNCT02332707 · 443 enrolled
  3. Dec 9, 2015Named ruzasvirINNProposed as its International Nonproprietary Name in WHO's List 114
  4. Jan 25, 2016Phase 1 study in Hepatitis C, ChronicNCT02666352 · 24 enrolled
  5. Apr 29, 2016Phase 2 study in Hepatitis C, ChronicNCT02759315 · 160 enrolled
  6. Nov 2, 2016Phase 2 study in Hepatitis CNCT02956629 · 282 enrolled

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Nonstructural protein 5A inhibitor”ChEMBL 37, by rule

Studies

All 5 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02956629Hepatitis C2TerminatedDec 22, 2017282
NCT02759315Hepatitis C, Chronic2TerminatedJul 27, 2017160
NCT02666352Hepatitis C, Chronic1CompletedJan 16, 201724
NCT02332707Hepatitis C2CompletedSep 16, 2016443
NCT02076100Hepatitis C1CompletedNov 15, 201522

How it is read

Names in the registry

  • “Ruzasvir”, 5 entries
  • “Bemnifosbuvir/Ruzasvir (BEM/RZR)”, 1 entry
  • “Ruzasvir 60 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.